View ValuationAvia Avian 将来の成長Future 基準チェック /16Avia Avian利益と収益がそれぞれ年間5.8%と5.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.6% 4.5%なると予測されています。主要情報5.8%収益成長率4.50%EPS成長率Chemicals 収益成長43.0%収益成長率5.4%将来の株主資本利益率18.61%アナリストカバレッジLow最終更新日10 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesRecent Insider Transactions • Jul 02President Commissioner recently bought €1.7m worth of stockOn the 24th of June, Hermanto Tanoko bought around 114m shares on-market at roughly €0.015 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €2.0m more in shares than they have sold in the last 12 months.Buy Or Sell Opportunity • Jun 10Now 41% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to €0.014. The fair value is estimated to be €0.024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has grown by 7.7%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 8.0% in the next 2 years.Board Change • Jun 08No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 12PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026.お知らせ • Mar 03PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025, at 09:30 FLE Standard Time.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Share price has been volatile over the past 3 months (7.8% average weekly change).Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: Rp5.81 (vs Rp5.39 in 3Q 2023)Third quarter 2024 results: EPS: Rp5.81 (up from Rp5.39 in 3Q 2023). Revenue: Rp1.78t (up 7.8% from 3Q 2023). Net income: Rp352.2b (up 5.5% from 3Q 2023). Profit margin: 20% (in line with 3Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany.Buy Or Sell Opportunity • Sep 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.026. The fair value is estimated to be €0.033, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 17% in the next 2 years.Buy Or Sell Opportunity • Aug 04Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.025. The fair value is estimated to be €0.032, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 14% in the next 2 years.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp5.90 (vs Rp6.29 in 2Q 2023)Second quarter 2024 results: EPS: Rp5.90 (down from Rp6.29 in 2Q 2023). Revenue: Rp1.72t (flat on 2Q 2023). Net income: Rp362.0b (down 7.1% from 2Q 2023). Profit margin: 21% (down from 23% in 2Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany.Reported Earnings • Apr 30First quarter 2024 earnings released: EPS: Rp7.24 (vs Rp6.73 in 1Q 2023)First quarter 2024 results: EPS: Rp7.24 (up from Rp6.73 in 1Q 2023). Revenue: Rp1.91t (up 6.9% from 1Q 2023). Net income: Rp446.2b (up 7.1% from 1Q 2023). Profit margin: 23% (in line with 1Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.Upcoming Dividend • Apr 16Upcoming dividend of Rp11.00 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 30 April 2024. Payout ratio is on the higher end at 93%, and the cash payout ratio is above 100%. Trailing yield: 4.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (4.8%).Board Change • Apr 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 29Full year 2023 earnings released: EPS: Rp26.51 (vs Rp22.61 in FY 2022)Full year 2023 results: EPS: Rp26.51 (up from Rp22.61 in FY 2022). Revenue: Rp7.02t (up 4.8% from FY 2022). Net income: Rp1.64t (up 17% from FY 2022). Profit margin: 23% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (93% payout ratio). Share price has been volatile over the past 3 months (7.1% average weekly change).Buy Or Sell Opportunity • Jan 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to €0.033. The fair value is estimated to be €0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp5.39 (vs Rp4.89 in 3Q 2022)Third quarter 2023 results: EPS: Rp5.39 (up from Rp4.89 in 3Q 2022). Revenue: Rp1.66t (up 4.9% from 3Q 2022). Net income: Rp333.7b (up 10% from 3Q 2022). Profit margin: 20% (up from 19% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.Upcoming Dividend • Oct 18Upcoming dividend of Rp11.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 24 October 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 48% and this is well supported by cash flows. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (6.3%).Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: Rp6.29 (vs Rp6.32 in 2Q 2022)Second quarter 2023 results: EPS: Rp6.29 (down from Rp6.32 in 2Q 2022). Revenue: Rp1.73t (flat on 2Q 2022). Net income: Rp389.9b (flat on 2Q 2022). Profit margin: 23% (in line with 2Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.Board Change • May 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 25Upcoming dividend of Rp11.00 per share at 3.9% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 09 May 2023. Payout ratio and cash payout ratio are on the higher end at 93% and 87% respectively. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.4%).Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 04Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: Rp6.32. Revenue: Rp1.74t (flat on 2Q 2021). Net income: Rp391.7b (up Rp391.7b from 2Q 2021). Profit margin: 23% (up from null in 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.7% growth forecast for the industry in Germany.Board Change • Aug 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測DB:P2C - アナリストの将来予測と過去の財務データ ( )IDR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20289,803,8602,027,0951,781,5672,193,850512/31/20279,203,6451,920,4191,614,4332,064,375512/31/20268,718,6611,748,1911,267,6501,862,22553/31/20268,462,9681,803,5461,552,2662,011,082N/A12/31/20258,123,6851,747,4621,275,0081,738,165N/A9/30/20257,994,3741,693,7111,140,2101,712,841N/A6/30/20257,735,1151,638,6271,108,8481,614,350N/A3/31/20257,584,9331,665,1491,292,8811,782,947N/A12/31/20247,471,3561,664,3411,317,0461,766,128N/A9/30/20247,257,8761,662,2951,390,5181,730,372N/A6/30/20247,129,4561,643,7961,150,6321,461,701N/A3/31/20247,140,3081,671,6471,400,9071,673,343N/A12/31/20237,016,8821,642,1661,385,9861,640,834N/A9/30/20236,899,9221,460,5721,597,2741,807,331N/A6/30/20236,822,7801,430,0691,751,5301,945,160N/A3/31/20236,836,7361,431,8851,454,5831,632,657N/A12/31/20226,694,1711,400,5611,276,9061,461,499N/A9/30/20226,760,5871,455,9981,139,3891,321,814N/A6/30/20226,925,3521,490,8731,015,4871,181,247N/A3/31/20226,618,0551,365,193923,7281,082,994N/A12/31/20216,779,6431,434,6131,133,5141,271,999N/A12/31/20205,731,2611,136,1471,682,7931,802,054N/A12/31/20195,669,732959,368N/A946,584N/A12/31/20185,122,1721,038,022N/A736,066N/A12/31/20174,311,557801,143N/A751,249N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: P2Cの予測収益成長率 (年間5.8% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: P2Cの収益 ( 5.8% ) German市場 ( 16.9% ) よりも低い成長が予測されています。高成長収益: P2Cの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: P2Cの収益 ( 5.4% ) German市場 ( 6.6% ) よりも低い成長が予測されています。高い収益成長: P2Cの収益 ( 5.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: P2Cの 自己資本利益率 は、3年後には低くなると予測されています ( 18.6 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 20:47終値2026/07/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Avia Avian Tbk 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Nashrullah Putra SulaemanDBS Bank LtdBryan SoegiantoDBS Bank Ltdnull nullMaybank Research Pte. Ltd.6 その他のアナリストを表示
Recent Insider Transactions • Jul 02President Commissioner recently bought €1.7m worth of stockOn the 24th of June, Hermanto Tanoko bought around 114m shares on-market at roughly €0.015 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €2.0m more in shares than they have sold in the last 12 months.
Buy Or Sell Opportunity • Jun 10Now 41% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to €0.014. The fair value is estimated to be €0.024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has grown by 7.7%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 8.0% in the next 2 years.
Board Change • Jun 08No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 12PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026.
お知らせ • Mar 03PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025, at 09:30 FLE Standard Time.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Share price has been volatile over the past 3 months (7.8% average weekly change).
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: Rp5.81 (vs Rp5.39 in 3Q 2023)Third quarter 2024 results: EPS: Rp5.81 (up from Rp5.39 in 3Q 2023). Revenue: Rp1.78t (up 7.8% from 3Q 2023). Net income: Rp352.2b (up 5.5% from 3Q 2023). Profit margin: 20% (in line with 3Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany.
Buy Or Sell Opportunity • Sep 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.026. The fair value is estimated to be €0.033, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 17% in the next 2 years.
Buy Or Sell Opportunity • Aug 04Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.025. The fair value is estimated to be €0.032, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 14% in the next 2 years.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp5.90 (vs Rp6.29 in 2Q 2023)Second quarter 2024 results: EPS: Rp5.90 (down from Rp6.29 in 2Q 2023). Revenue: Rp1.72t (flat on 2Q 2023). Net income: Rp362.0b (down 7.1% from 2Q 2023). Profit margin: 21% (down from 23% in 2Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Apr 30First quarter 2024 earnings released: EPS: Rp7.24 (vs Rp6.73 in 1Q 2023)First quarter 2024 results: EPS: Rp7.24 (up from Rp6.73 in 1Q 2023). Revenue: Rp1.91t (up 6.9% from 1Q 2023). Net income: Rp446.2b (up 7.1% from 1Q 2023). Profit margin: 23% (in line with 1Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
Upcoming Dividend • Apr 16Upcoming dividend of Rp11.00 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 30 April 2024. Payout ratio is on the higher end at 93%, and the cash payout ratio is above 100%. Trailing yield: 4.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (4.8%).
Board Change • Apr 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 29Full year 2023 earnings released: EPS: Rp26.51 (vs Rp22.61 in FY 2022)Full year 2023 results: EPS: Rp26.51 (up from Rp22.61 in FY 2022). Revenue: Rp7.02t (up 4.8% from FY 2022). Net income: Rp1.64t (up 17% from FY 2022). Profit margin: 23% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (93% payout ratio). Share price has been volatile over the past 3 months (7.1% average weekly change).
Buy Or Sell Opportunity • Jan 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to €0.033. The fair value is estimated to be €0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp5.39 (vs Rp4.89 in 3Q 2022)Third quarter 2023 results: EPS: Rp5.39 (up from Rp4.89 in 3Q 2022). Revenue: Rp1.66t (up 4.9% from 3Q 2022). Net income: Rp333.7b (up 10% from 3Q 2022). Profit margin: 20% (up from 19% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
Upcoming Dividend • Oct 18Upcoming dividend of Rp11.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 24 October 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 48% and this is well supported by cash flows. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (6.3%).
Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: Rp6.29 (vs Rp6.32 in 2Q 2022)Second quarter 2023 results: EPS: Rp6.29 (down from Rp6.32 in 2Q 2022). Revenue: Rp1.73t (flat on 2Q 2022). Net income: Rp389.9b (flat on 2Q 2022). Profit margin: 23% (in line with 2Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.
Board Change • May 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 25Upcoming dividend of Rp11.00 per share at 3.9% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 09 May 2023. Payout ratio and cash payout ratio are on the higher end at 93% and 87% respectively. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.4%).
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 04Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: Rp6.32. Revenue: Rp1.74t (flat on 2Q 2021). Net income: Rp391.7b (up Rp391.7b from 2Q 2021). Profit margin: 23% (up from null in 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.7% growth forecast for the industry in Germany.
Board Change • Aug 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.